Ishara Investments LP Invests $3.58 Million in Nuvation Bio Inc. $NUVB

Ishara Investments LP purchased a new position in shares of Nuvation Bio Inc. (NYSE:NUVB) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 400,000 shares of the company’s stock, valued at approximately $3,584,000. Nuvation Bio comprises 4.1% of Ishara Investments LP’s investment portfolio, making the stock its 7th biggest position.

Other hedge funds also recently modified their holdings of the company. Capricorn Fund Managers Ltd acquired a new position in shares of Nuvation Bio during the 4th quarter worth $14,236,000. JPMorgan Chase & Co. increased its stake in shares of Nuvation Bio by 472.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 675,600 shares of the company’s stock worth $2,500,000 after purchasing an additional 557,656 shares during the last quarter. Aisling Capital Management LP increased its stake in shares of Nuvation Bio by 16.5% during the 3rd quarter. Aisling Capital Management LP now owns 2,960,659 shares of the company’s stock worth $10,954,000 after purchasing an additional 419,650 shares during the last quarter. NEOS Investment Management LLC increased its stake in shares of Nuvation Bio by 80.8% during the 3rd quarter. NEOS Investment Management LLC now owns 252,522 shares of the company’s stock worth $934,000 after purchasing an additional 112,874 shares during the last quarter. Finally, ACT Capital Management LLC acquired a new position in shares of Nuvation Bio during the 4th quarter worth $5,470,000. Institutional investors and hedge funds own 61.67% of the company’s stock.

Nuvation Bio Price Performance

NYSE NUVB opened at $5.33 on Thursday. The company has a current ratio of 7.44, a quick ratio of 7.24 and a debt-to-equity ratio of 0.15. The company has a fifty day simple moving average of $4.78 and a 200 day simple moving average of $5.81. The company has a market cap of $1.86 billion, a P/E ratio of -12.40 and a beta of 1.52. Nuvation Bio Inc. has a 1 year low of $1.58 and a 1 year high of $9.75.

Nuvation Bio (NYSE:NUVB) last posted its quarterly earnings data on Monday, May 4th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.04. Nuvation Bio had a negative net margin of 102.06% and a negative return on equity of 44.10%. The business had revenue of $83.23 million during the quarter, compared to the consensus estimate of $66.22 million. On average, sell-side analysts predict that Nuvation Bio Inc. will post -0.39 EPS for the current year.

Insider Buying and Selling at Nuvation Bio

In other Nuvation Bio news, insider Dongfang Liu sold 50,000 shares of the stock in a transaction on Friday, April 17th. The shares were sold at an average price of $5.02, for a total value of $251,000.00. Following the completion of the sale, the insider directly owned 18,000 shares of the company’s stock, valued at $90,360. This represents a 73.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Mashal purchased 25,000 shares of Nuvation Bio stock in a transaction on Tuesday, June 9th. The stock was bought at an average cost of $4.73 per share, with a total value of $118,250.00. Following the completion of the acquisition, the director owned 225,000 shares in the company, valued at approximately $1,064,250. This trade represents a 12.50% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold a total of 286,750 shares of company stock valued at $1,339,118 in the last ninety days. Company insiders own 30.11% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on NUVB shares. Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Nuvation Bio in a report on Tuesday, May 5th. Zacks Research downgraded shares of Nuvation Bio from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 26th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Nuvation Bio in a report on Tuesday, May 5th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Nuvation Bio in a report on Tuesday, May 5th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Nuvation Bio in a report on Wednesday, June 10th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $12.50.

Nuvation Bio Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.